1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
141.39 USD   +2.12%
05/27INSIDER SELL : Seagen
MT
05/26Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS« Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
CI
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Seagen

11/08/2021 | 07:20am EDT


ę MT Newswires 2021
All news about SEAGEN INC.
05/27INSIDER SELL : Seagen
MT
05/26Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS« Combinatio..
CI
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positiv..
MT
05/23SEAGEN : Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« (..
PU
05/23SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« ..
BU
05/23Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUK..
CI
05/23SEAGEN INC. : SEC Filing 8K
CO
05/19SEAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 793 M - -
Net income 2022 -651 M - -
Net cash 2022 1 615 M - -
P/E ratio 2022 -39,9x
Yield 2022 -
Capitalization 26 026 M 26 026 M -
EV / Sales 2022 13,6x
EV / Sales 2023 9,62x
Nbr of Employees 2 675
Free-Float 99,2%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 141,39 $
Average target price 160,94 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-8.54%26 026
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
ICON PUBLIC LIMITED COMPANY-26.61%18 478
CELLTRION, INC.-21.21%17 245